J2X-MC-PYAD - ClinicalTrials.gov - NCT04497987
J2X-MC-PYAD - ClinicalTrials.gov - NCT04497987
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must either live or work in a nursing home that has at least one confirmed case of COVID-19 with the last week
Participants must agree to the collection of several blood samples and swab samples from the nose
Participants must have venous access sufficient to allow intravenous infusions and blood sampling
Participant or legally authorized representative must give signed informed consent
Participants must agree to approved birth control to prevent pregnancy
Participants must NOT
Participants must not be in the hospital
Participants must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
COVID-19 (Coronavirus)
What the trial is testing?
LY3819253, LY-CoV555, Bamlanivimab, Etsesevimab, LY3832479, LY-CoV016
Could I receive a Placebo?
yes
Enrollment Goal
5000
Trial Dates
August 2020 - June 2021
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must either live or work in a nursing home that has at least one confirmed case of COVID-19 with the last week
Participants must agree to the collection of several blood samples and swab samples from the nose
Participants must have venous access sufficient to allow intravenous infusions and blood sampling
Participant or legally authorized representative must give signed informed consent
Participants must agree to approved birth control to prevent pregnancy
Participants must NOT
Participants must not be in the hospital
Participants must not be pregnant or breastfeeding
Trial Summary
Conditions the trial is for
COVID-19 (Coronavirus)
What the trial is testing?
LY3819253, LY-CoV555, Bamlanivimab, Etsesevimab, LY3832479, LY-CoV016
Could I receive a Placebo?
yes
Enrollment Goal
5000
Trial Dates
August 2020 - June 2021
Trial Phase
3
Trial Locations
Hide locations not currently recruiting